Abstract
5-Aminolaevulinic acid (ALA)-induced porphyrin biosynthesis, which is used for ALA-based photodynamic therapy (ALA-PDT), was studied in tissues of 10 patients with Barrett's oesophagus (BE) and adenocarcinoma of the oesophagus (AC) undergoing oesophagectomy at a mean time interval of 6.7 h after the ingestion of ALA (60 mg kg–1). In BE, AC, squamous epithelium (SQ) and gastric cardia, the activities of the haem biosynthetic enzymes porphobilinogen deaminase (PBG-D) and ferrochelatase (FC) and the PDT power index – the ratio between PBG-D and FC in BE and AC in comparison with SQ – were determined before ALA ingestion. Following ALA administration, ALA, porphobilinogen, uroporphyrin I and PPIX were determined in tissues and plasma. The PDT power index did not predict the level of intracellular accumulation of PPIX found at 6.7 h. In BE, there was no selectivity of PPIX accumulation compared to SQ, whereas in half of patients with AC selectivity was found. Higher haem biosynthetic enzyme activities (i.e. PBG-D) and lower PPIX precursor concentrations were found in BE and AC compared to SQ. It is therefore possible that PPIX levels will peak at earlier time intervals in BE and AC compared to SQ. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC and Krasner N (1996) Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 348: 584–585
Bishop DF and Desnick RJ (1982) Assays of the heme biosynthetic enzymes. Preface. Enzyme 28: 91–93
Cameron AJ and Carpenter HA (1997) Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 92: 586–591
Clark GW, Ireland AP and DeMeester TR (1996) Dysplasia in Barrett's esophagus: diagnosis, surveillance and treatment. Dig Dis 14: 213–227
Drewitz DJ, Sampliner RE and Garewal HS (1997) The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 92: 212–215
Edwards MJ, Gable DR, Lentsch AB and Richardson JD (1996) The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. Ann Surg 223: 585–589
Goldberg A and McGillion FB (1973) Proceedings: central uptake and cardiovascular effects of delta-aminolaevulinic acid. Br J Pharmacol 49: 178P
Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG and Ell C (1998) Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 114: 448–455
Haggitt RC (1994) Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 25: 982–993
Hameeteman W, Tytgat GN, Houthoff HJ and van den Tweel JG (1989) Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 96: 1249–1256
Henderson BW and Dougherty TJ (1992) How does photodynamic therapy work?. Photochem Photobiol 55: 145–157
Herman MA, Webber J, Fromm D and Kessel D (1998) Hemodynamic effects of 5-aminolevulinic acid in humans. J Photochem Photobiol B 43: 61–65
Hinnen P, de Rooij FWM, Velthuysen van MLF, Edixhoven A, Hillegersberg van R, Tilanus HW, Wilson JHP and Siersema PD (1998) Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the esophagus. Br J Cancer 78: 679–682
Hinnen P, de Rooij FWM, Voortman G, Tilanus HW, Wilson JHP and Siersema PD 2000a) Acrylate yellow filters in operating lights protect against photosensitization tissue damage. Br J Surg 87: 231–235
Hinnen P, Siersema PD, Edixhoven A, Wilson JHP and de Rooij FWM 2000b). Ferrochelatase activity inhibition by 5-aminolaevulinic acid-induced photodynamic therapy, submitted for publication
inuma S, Farshi SS, Ortel B and Hasan T (1994) A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin. Br J Cancer 70: 21–28
Kennedy JC and Pottier RH (1992) Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 14: 275–292
Li G, Szewczuk MR, Pottier RH and Kennedy JC (1999) Effect of mammalian cell differentiation on response to exogenous 5-aminolevulinic acid. Photochem Photobiol 69: 231–235
Lowry O, Rosebrough N, Farr A and Randall R (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem 193: 265–275
Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, Hatfield AR and Bown SG (1995) Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX – a pilot study. Gut 36: 67–75
van den Boogert J, van Hillegersberg R, de Rooij FW, de Bruin RW, Edixhoven-Bosdijk A, Houtsmuller AB, Siersema PD, Wilson JH and Tilanus HW (1998) 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J Photochem Photobiol B 44: 29–38
van der Burgh A, Dees J, Hop WC and van Blankenstein M (1996) Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 39: 5–8
van Hillegersberg R, van den Berg JW, Kort WJ, Terpstra OT and Wilson JH (1992) Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology 103: 647–651
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hinnen, P., de Rooij, F., Terlouw, E. et al. Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid. Br J Cancer 83, 539–543 (2000). https://doi.org/10.1054/bjoc.2000.1300
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1300
Keywords
This article is cited by
-
Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study
BMC Cancer (2021)
-
Metronomic photodynamic therapy using an implantable LED device and orally administered 5-aminolevulinic acid
Scientific Reports (2020)
-
Kinetics of porphyrin fluorescence accumulation in pediatric brain tumor cells incubated in 5-aminolevulinic acid
Acta Neurochirurgica (2014)
-
Technology Insight: photodynamic therapy for cholangiocarcinoma
Nature Clinical Practice Gastroenterology & Hepatology (2006)
-
Traitement photodynamique des cholangiocarcinomes
Acta Endoscopica (2003)